SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
604.00    4.00 (0.67%)
Bid:
602.00
Ask:
605.00
Spread: 3.00 (0.498%)
Market Cap: £730.89m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Oxford Biomedica News

Oxford Biomedica wins new agreement for LentiVector platform
5 Jan 2022

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica signs licence, supply deal with Cabaletta Bio
5 Jan 2022

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector ...

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC
15 Dec 2021

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Oxford Biomedica in license and supply deals with Novartis and Arcellx
13 Dec 2021

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica strikes new license and supply agreements
13 Dec 2021

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Oxford BioMedica licences technology for cystic fibrosis treatment
19 Oct 2021

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology
19 Oct 2021

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option...

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold
30 Sep 2021

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold